1. Combinatorial effects of cannabinoid receptor 1 and 2 agonists on characteristics and proteomic alteration in MDA-MB-231 breast cancer cells.
- Author
-
Chutoe C, Inson I, Krobthong S, Phueakphud N, Khunluck T, Wongtrakoongate P, Charoenphandhu N, and Lertsuwan K
- Subjects
- Humans, Cell Line, Tumor, Female, Triple Negative Breast Neoplasms metabolism, Triple Negative Breast Neoplasms pathology, Triple Negative Breast Neoplasms drug therapy, Cell Movement drug effects, Cannabinoid Receptor Agonists pharmacology, Pseudopodia drug effects, Pseudopodia metabolism, Breast Neoplasms metabolism, Breast Neoplasms pathology, Breast Neoplasms drug therapy, Neoplasm Invasiveness, Axl Receptor Tyrosine Kinase, Proteome metabolism, Indoles pharmacology, Cell Cycle Checkpoints drug effects, Receptor Protein-Tyrosine Kinases metabolism, Receptor, Cannabinoid, CB1 metabolism, Receptor, Cannabinoid, CB1 agonists, Cell Proliferation drug effects, Proteomics methods, Receptor, Cannabinoid, CB2 agonists, Receptor, Cannabinoid, CB2 metabolism
- Abstract
Breast cancer is the most common cancer diagnosed in women worldwide. However, the effective treatment for breast cancer progression is still being sought. The activation of cannabinoid receptor (CB) has been shown to negatively affect breast cancer cell survival. Our previous study also reported that breast cancer cells responded to various combinations of CB1 and CB2 agonists differently. Nonetheless, the mechanism underlying this effect and whether this phenomenon can be seen in other cancer characteristics remain unknown. Therefore, this study aims to further elucidate the effects of highly selective CB agonists and their combination on triple-negative breast cancer proliferation, cell cycle progression, invasion, lamellipodia formation as well as proteomic profile of MDA-MB-231 breast cancer cells. The presence of CB agonists, specifically a 2:1 (ACEA: GW405833) combination, prominently inhibited colony formation and induced the S-phase cell cycle arrest in MDA-MB-231 cells. Furthermore, cell invasion ability and lamellipodia formation of MDA-MB-231 were also attenuated by the exposure of CB agonists and their 2:1 combination ratio. Our proteomic analysis revealed proteomic profile alteration in MDA-MB-231 upon CB exposure that potentially led to breast cancer suppression, such as ZPR1/SHC1/MAPK-mediated cell proliferation and AXL/VAV2/RAC1-mediated cell motility pathways. Our findings showed that selective CB agonists and their combination suppressed breast cancer characteristics in MDA-MB-231 cells. The exposure of CB agonists also altered the proteomic profile of MDA-MB-231, which could lead to cell proliferation and motility suppression., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Chutoe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF